Ticker Launch

SPAC · Merger completed

Phoenix Biotech Acquisition Corp.

Business combination with CERo Therapeutics, Inc.

Phoenix Biotech Acquisition Corp. is a blank-check company (SPAC) that raised $155M in its initial public offering on Oct 8, 2021, listing on Nasdaq Global Market. It completed its business combination with CERo Therapeutics, Inc. on Feb 14, 2024; the combined company is CERo Therapeutics Holdings, Inc. (CERO). Cantor led the IPO. Ellenoff Grossman & Schole advised the underwriters on the IPO.

CERo Therapeutics is an immunotherapy company developing engineered T cell therapeutics for the treatment of cancer. It is the target of a proposed business combination with Phoenix Biotech Acquisition Corp.

Status
Merger completed
IPO date
Oct 8, 2021
IPO size
$155M
IPO exchange
Nasdaq Global Market
Target
CERo Therapeutics, Inc.
Announced
Jun 5, 2023
Closed
Feb 14, 2024
Combined company
CERo Therapeutics Holdings, Inc. (CERO)
IPO underwriters
Cantor
Underwriters' counsel (IPO)
Ellenoff Grossman & Schole

More on this SPAC for subscribers

Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.

Then $99/month or $999/year. Cancel anytime.

Filings

Other deSPACs that closed in 2024